Which antipsychotic agents are patients with schizophrenia most likely to stop taking?

Updated: Mar 16, 2018
  • Author: Frances R Frankenburg, MD; Chief Editor: Glen L Xiong, MD  more...
  • Print

EUFEST (European First Episode Schizophrenia Trial) was a year-long open-label study conducted in nearly 500 patients in 13 European countries and Israel that, as did CATIE, used treatment discontinuance as the main outcome measure. The study found that patients were more likely to stop low-dose haloperidol than to stop olanzapine, quetiapine, ziprasidone, or amisulpride (not available in the United States); however, all medications were associated with similar decreases in symptoms. [86]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!